Long-term Efficacy of Maintenance Bacillus Calmette-Guérin versus Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-up-Reference-Cited by-同舟云学术

Long-term Efficacy of Maintenance Bacillus Calmette-Guérin versus Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-up

Published:2009-08 Issue:2 Volume:56 Page:260-265
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Järvinen Riikka,Kaasinen Eero,Sankila Anna,Rintala Erkki

Publisher

Elsevier BV

Subject

Urology

Reference21 articles.

1. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials;Sylvester;Eur Urol,2006

2. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder;Babjuk;Eur Urol,2008

3. Intravesical bacillus Calmette-Guérin versus mitomycin-C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity;Böhle;J Urol,2003

4. Intravesical bacillus Calmette-Guérin in superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials;Shelley;BJU Int,2004

5. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guérin (BCG) in patients with non–muscle-invasive bladder carcinoma;Friedrich;Eur Urol,2007

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter to the editor: Multiparametric MRI-based VI-RADS: Can it predict 1- to 5-year recurrence of bladder cancer?;European Radiology;2024-08-30

2. Relationship between clonal evolution and drug resistance in bladder cancer: A genomic research review;Pharmacological Research;2024-08

3. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08

4. Contemporary Treatment of NMIBC—Is It Time to Move on from BCG?;Journal of Clinical Medicine;2024-07-14

5. Mitomycin C vs. Bacillus Calmette–Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients—A comparative analysis from a single center;Urologic Oncology: Seminars and Original Investigations;2024-07